Sign up to our newsletter Subscribe
We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
